EuroBiotech: More Articles of Note

(NS Newsflash/CC BY 2.0)

> Symphogen moved antibodies against LAG3 and TIM3 into phase 1. The Danish biotech discovered the immuno-oncology prospects in the 2016 pact it formed with Shire. Statement 

> BioNTech named Özlem Türeci, M.D., as its CMO. Türeci founded and later led Ganymed Pharmaceuticals, which was bought by Astellas for €422 million ($494 million) upfront in 2016. Release   

> Treeway stepped up preparations for a phase 3 amyotrophic lateral sclerosis trial after bringing its asset through an early test of bioavailability and safety. The Dutch biotech is developing an oral formulation of Radicava. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Bayer and Boehringer Ingelheim contributed to High-Tech Gründerfonds’ third fund. The pharma companies helped the German seed fund raise €316.5 million ($370 million) for its latest investment vehicle. Release

> Allergy Therapeutics posted clinical data on its house-dust mite immunotherapy. Statement  

> Evotec and Arix Bioscience entered into a strategic collaboration with Fred Hutchinson Cancer Research Center. The partners will create and support cancer and infectious disease startups. Release

Suggested Articles

Acceleron’s sotatercept outdid placebo at reducing pulmonary vascular resistance in patients with pulmonary arterial hypertension.

China’s Biotheus picked up the rights to Tilt Biotherapeutics’ lead oncolytic virus program in greater China.

A Cedars-Sinai team used stem cells to uncover a key mechanism of young onset Parkinson's, as well as a potential remedy—an existing skin treatment.